KALV - KalVista Pharmaceuticals CFO discloses sale of 40855 shares
2024-02-16 16:31:07 ET
More on KalVista Pharmaceticals
- KalVista Is Still Cheap After Phase 3 Hereditary Angioedema Data
- KalVista: Positive Results From Phase 3 Trial Pave The Way For Commercialization (Downgrade)
- KalVista Pharmaceuticals up 16%, prices $160M offering
- Two biotech/pharma stocks to watch - STTK, KALV